Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000922

Drug Information
NameAcetohexamide
SynonymsCCRIS 4; Prestwick2_000055; Acetohexamida [INN-Spanish]; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; EU-0100088; SPBio_002130; BPBio1_000231; Lopac0_000088; D000092; C06806; CAS-968-81-0; Acetohexamidum; 8054-32-8; Metaglucina; NCGC00091230-02; Acetohexamide Salvat Brand; Minoral; Dymelor; HSDB 3280; 4-Acetyl-N-[(cyclohexylamino)- carbonyl]benzenesulfonamide; HMS2093H21; Acetohexamide [USAN:INN:BAN:JAN]; Lopac-A-178; NCGC00091230-01; Acetohexamida; U-14812; Dimelin; Ordimel; Acetohexamid; CID1989; Acetohexamide Lilly Brand; 968-81-0; DB00414; NCI-C03247; Salvat Brand of Acetohexamide; ord imel; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; NCGC00015014-01; dimelin (antidiabetic); Prestwick_3; BSPBio_000209; NCGC00015014-03; NCGC00091230-03; Urea, 1-((p-acetylphenyl)sulfonyl)-3-cyclohexyl-; A178_SIGMA; Acetohexamide (JP15/USP/INN); 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; MolPort-003-666-680; NCGC00091230-04; Prestwick0_000055; MLS002154186; Prestwick1_000055; NCGC00016555-01; Benzenesulfonamide, 4-acetyl-N-[(cyclohexylamino)carbonyl]-; D00219; Hypoglicil; Lilly Brand of Acetohexamide; CHEBI:28052; Gamadiabet; A-178; UNII-QGC8W08I6I; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; C15H20N2O4S; LS-2019; AC1L1COE; Dymelor (TN); Prestwick3_000055; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide; Benzenesulfonamide, 4-acetyl-N-((cyclohexylamino)carbonyl)-; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; BRN 2225115; HMS1568K11; U 14812; BRD-K52960356-001-03-1; EINECS 213-530-4; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; Dimelor; Tsiklamid; A178_FLUKA; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; Acetohexamidum [INN-Latin]; acetohexamide; SMR001233477; NCGC00015014-07; CHEMBL1589
IndicationDiabetes mellitus
[ICD9: 250   ICD10: E08-E13]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13
-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
InChIKeyVGZSUPCWNCWDAN-UHFFFAOYSA-N
Canonical SMILESCC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2    
Therapeutic ClassHypoglycemic Agents
CAS NumberCAS 968-81-0
FormulaC15H20N2O4S
PubChem Compound IDCID 1989.
PubChem Substance IDSID 9025.
ChEBI28052;
SuperDrug ATC IDA10BB31
A10BB31
TargetATP-sensitive potassium channel (KATP channel)Binder[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071893 To Reference
Ref 2Studies for analyzing the prohibited ingredients such as acetohexamide in cosmetics. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2005;(123):19-22. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543